Skip to main content
VOLITIONRX LTD logo

VOLITIONRX LTD — Investor Relations & Filings

Ticker · VNRX ISIN · US9286611077 US Professional, scientific and technical activities
Filings indexed 1,105 across all filing types
Latest filing 2026-04-30 Annual Report
Country US United States of America
Listing US VNRX

About VOLITIONRX LTD

https://volition.com/

VolitionRx Ltd. is an epigenetics company that develops blood tests for the early diagnosis and monitoring of life-altering diseases in both humans and animals. The company's core technology is its proprietary Nu.Q® platform, which is based on the science of Nucleosomics. This platform detects and quantifies characteristic changes in circulating nucleosomes, which are fragments of chromatin released from cells. These nucleosomes act as biomarkers for various conditions, enabling the development of simple, cost-effective, and non-invasive tests. VolitionRx's primary focus is on applications for detecting and monitoring cancers and sepsis, with the goal of improving patient outcomes by making diagnostics more accessible.

Recent filings

Filing Released Lang Actions
10-K/A - VOLITIONRX LTD (0000093314) (Filer)
Annual Report
2026-04-30 English
8-K - VOLITIONRX LTD (0000093314) (Filer)
Regulatory Filings
2026-04-28 English
8-K - VOLITIONRX LTD (0000093314) (Filer)
Regulatory Filings
2026-04-23 English
8-K - VOLITIONRX LTD (0000093314) (Filer)
Regulatory Filings
2026-04-17 English
10-K - VOLITIONRX LTD (0000093314) (Filer)
Annual Report FY 2025
2026-03-31 English
8-K - VOLITIONRX LTD (0000093314) (Filer)
Regulatory Filings
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.